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Abstract 
Background: There is a strong association between factor VIII (FVIII) and presence of 
cardiovascular disease (CVD). Exercise is a known trigger for myocardial infarction, and 
the majority of ischemic events from physical stress occur due to an occlusive thrombus. 
FVIII increases acutely with exercise and remains elevated hours after exercise. 
Furthermore, FVIII is also higher in cigarette smokers, however, it has not been 
investigated in e-cigarette smokers. The purpose of this study is to identify potential 
differences in FVIII before exercise, after exercise, and its magnitude of change in e-
cigarette users versus non-users. 
Methods: Eighteen individuals (8 e-cigarette users, 3 women and 5 men, and 10 non-
smokers, 7 women and 3 men; age, 18-32 years old) were recruited to participate in this 
research study. An incremental test to exhaustion (x̄=12.20 ± 3.20 minutes) was 
performed on an electronically braked cycle ergometer (Lode Corival cpet; Groningen, 
Netherlands) to determine the peak rate of oxygen consumption (VO2peak). Ten mL of 
blood was drawn into a citrate anticoagulant solution from an antecubital vein using clean 
venipuncture with minimal stasis both prior to and immediately following exercise 
testing. A commercially available ELISA kit was used to determine plasma 
concentrations of coagulation FVIII antigen. 
Results: There was no significant difference between smokers (N = 8, 4.35 ± 2.09 IU/ml) 
and nonsmokers (N = 9, 5.02 ± 4.87 IU/ml, p=0.72) for resting FVIII antigen. There was 
a main effect for exercise in that the post-exercise values (N=10, 7.76 ±1.40 IU/ml) were 
larger than pre-exercise values (N=10, 3.82 ± 0.65, p=0.003). However, there was no 
main effect for smoking and no smoking x exercise interaction (post-exercise smokers, 
N=4, 6.67 ± 1.46, post-exercise non-smokers, N= 7, 8.39 ± 5.81, p=0.58). 
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Conclusion: Our preliminary data suggests that e-cig use does not significantly affect 
FVIII or the FVIII response to exercise. 
 
 
 
Chapter I 
Introduction 
Clinical Importance of Hemostasis 
 Cardiovascular disease (CVD) is the leading cause of death in the United States, 
manifesting itself through ischemic events like myocardial infarction and stroke (13). A 
majority of these events are caused by plaque ruptures that form a clot inside either the 
plaque or the lumen of a blood vessel, leading to blockage of blood flow in the artery. 
There is autopsy evidence of atherosclerotic plaques in people without any history of 
myocardial infarction (16,44), suggesting plaque rupture alone is not sufficient to cause 
an ischemic event and must occur in combination with prothrombotic conditions. 
Therefore, blood coagulation and clot dissolution (or fibrinolysis) are clinically relevant. 
There is a strong association between coagulation and presence of CVD. In 
particular, fibrinogen is associated with CVD and related ischemic events. As a substrate 
converted to fibrin clot, fibrinogen promotes coagulation by enhancing platelet 
aggregation (38) and is linked with risk for CVD (20,46) coronary artery disease (CAD) 
(58), myocardial infarction (58,1), stroke (1), and mortality (1) in patients with CVD. 
Other important markers for blood coagulation include factors VII (FVII), and VIII 
(FVIII), von Willebrand Factor (vWF), and thrombin-antithrombin complex (TAT), a 
marker for thrombin formation. Like fibrinogen, all of these markers of coagulation 
potential are also associated with the presence of CVD (46), CAD (51), myocardial 
infarction (29), stroke (12), and mortality (12) in patients with CVD. Increased 
coagulation potential may also increase the progression of atherosclerosis, with higher 
rates of hypercoagulation in patients with peripheral artery disease (PAD) 
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(50).  However, coagulation potential is not the only factor impacting risk of ischemic 
events. 
There is also a strong connection between decreased fibrinolysis and the presence 
of CVD. The main enzyme involved in fibrinolysis is tissue plasminogen activator (tPA), 
which catalyzes the conversion of plasminogen to plasmin, resulting in fibrinogen 
dissolving into fibrin dimer proteins. The most prominent inhibitor of tPA is plasminogen 
activator inhibitor-1 (PAI-1), which binds to tPA and inhibits its function. Increases in 
PAI-1 and decreases in tPA activity are both associated with CVD (37), CAD (47), 
ischemic events (58), stroke (34), and mortality (30). The degree of impairment in the 
fibrinolytic potential also impacts the progression of PAD, with significantly lower tPA 
activity in patients with severe claudication compared to those with mild claudication 
(37). Furthermore, impaired fibrinolysis is independently associated with risk factors for 
CVD, like body composition (36), hyperlipidemia (29,31) diabetes mellitus, body mass 
index, low-density lipoprotein (36).  
Coagulation Responses to Exercise 
Exercise is a known trigger for myocardial infarction in roughly one-third of 
patients who can identify a trigger (59). Furthermore, ischemic events resulting from 
physical stress occur due to an occlusive clot more frequently than events unrelated to 
physical stress (22). Thus, coagulation and fibrinolytic responses to exercise have 
important clinical implications. 
Activated partial thromboplastin (APTT), a measure of the intrinsic and common 
pathway of coagulation, significantly decreases following exercise across sexes (7,25) 
and exercise modalities (52,60). However, this acute effect is not consistently seen on 
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prothrombin time (PT), with studies reporting both shortened (25) and unchanged (52) 
PTs after acute exercise. These inconclusive findings suggest that the extrinsic tissue 
factor pathway are not as involved in exercise-induced hemostatic responses (63).  
FVIII activity (FVIII:c) and FVIII antigen (FVIII:ag) increase acutely with 
exercise and remain elevated hours after exercise (4,61), with the magnitude of both 
responses being dependent on exercise intensity (41). Other markers, including TAT, 
prothrombin fragments 1 and 2 and fibrinopeptide A are increased following 1-hour of 
high intensity exercise but not following a moderate-intensity exercise of the same 
duration (64). There are no acute effects of exercise on FVII, with no observed changes 
in FVII:c following maximal exercise (60,61), no change in FVII:ag, FVII:ag/FVII:c 
ratio, and plasma concentrations of circulating activated FVII following exhaustive 
exercise (63). 
Although the specific mechanisms are uncertain, increased beta-adrenergic 
activity influences the coagulation response to exercise, as B-adrenergic blockade inhibits 
the exercise-induced increases in FVIII (14). Furthermore, platelet activation increases 
following an infusion of epinephrine or norepinephrine (26,39,40).  Another mechanism 
influencing the coagulation response to exercise is endogenous NO production. When 
partially blocking NO production, the exercise induced response in the vWF and FVIII is 
inhibited (32). Despite markers for coagulation increasing following acute exercise, 
results for fibrinogen are inconclusive with evidence showing both increases (4), 
decreases (6), and no change (23) in fibrinogen levels following acute exercise. 
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Fibrinolytic Responses to Exercise 
 Overall, fibrinolysis increases as a result of acute exercise due to increases in tPA 
activity paired with reductions in PAI-1 activity. Mechanistically, these fibrinolytic 
responses during exercise are due to an increased release of tPA from vascular 
endothelial cells (41). This mechanism occurs through hypoglycemia as well as increases 
in 1-deamino-8-D-arginine-vasopressin, epinephrine, and thrombin; all of which occur 
during acute exercise (49). This increase in tPA may be large enough to effectively 
reduce PAI-1 activity as PAI-1 forms an inactive, irreversible bond with tPA. 
 These fibrinolytic responses are magnified with increases in intensity. Streiff and 
Bell (57) reported significant increases in fibrinolysis do not usually occur until 
individuals reach 50% of their max heart rate (HR). With there being a proposed 
threshold intensity of 80-90% max HR for exponential changes in fibrinolytic activity to 
occur (17). The threshold-like exercise response pattern for epinephrine could explain 
these findings in fibrinolytic activity (42). However, Womack et al. (65) reported 
fibrinolytic responses below lactate threshold, with intensities above lactate threshold 
eliciting greater fibrinolytic responses. Duration can influence the fibrinolytic responses, 
but to a lesser degree than does intensity, as Womack et al. observed higher intensity 
exercise at a duration of 20 minutes leads to greater fibrinolytic responses than does 
moderate intensity, equicaloric work at a moderate intensity.  
The Effects of Smoking/Nicotine on Hemostasis 
Both direct and second-hand exposure to cigarette smoking decreases Nitric 
Oxide (NO) availability by altering the expression and activity of the endothelial NO 
synthase enzyme (3). Mechanistically, cigarette smoke contains high amounts of free 
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radicals that lead to the reduced bioavailability of NO. NO plays both a direct and 
indirect role in thrombosis by inhibiting platelet adhesion and aggregation and increasing 
platelet recruitment (28,53). Impaired NO bioavailability results in secretion of 
thromboxane A2 from the platelets, thus enhancing platelet aggregation (33). Exposure to 
cigarette smoke increases vWF and fibrinogen, contributing to this process and enhancing 
thrombosis. 
Higher plasma levels of fibrinogen and viscosity are the main contributors to 
higher coagulability found in smokers (43). Lifetime duration of smoking is a 
determinant of baseline fibrinogen levels; however, these levels quickly drop following 
smoking cessation. Cigarette smokers have significantly higher plasma fibrinogen than 
non-smokers (45,62,35), while pipe-cigar smokers show no significant difference from 
non-smokers (62). When these individuals were split into lighter (1-19 cigarettes/day) 
and heavier (20+ cigarettes/day) categories, heavier smokers had higher levels of 
fibrinogen (62). This increase is not unique to cigarette smoking, however, as hookah 
smokers have higher plasma fibrinogen in comparison to both non-smokers and cigarette 
smokers (54). 
Fibrinolysis is also impaired by cigarette usage, as tPA production and release 
being significantly lower in smokers compared to nonsmokers despite no significant 
difference in PAI-1 activity (8). Pretorius et al. observed smokers exhibited a reduced 
tPA release compared to non-smokers when stimulated with bradykinin, a stimulant for 
tPA release (48).  
There is no evidence that nicotine, the most integral ingredient found in cigarettes, 
has any effect on hemostasis. Oral and transdermal nicotine studies have found no 
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significant chronic influence on hemostatic markers in healthy adults (10). This would 
suggest the main cause for chronic hematological changes from smoking are caused by 
other ingredients embedded in the cigarette. 
 There is evidence from both epidemiological and experimental studies that 
particulate matter (PM), such as black carbon, nitrogen dioxide, and carbon monoxide, 
results in hypercoagulability and hypofibrinolysis. Plasma fibrinogen has been one of the 
most studied variables in both prospective cohort and experimental studies, with evidence 
suggesting increased fibrinogen levels from PM and ambient particles in concentrated 
doses (9,27,55). There is, however, no clear pattern for other pro-coagulant variables 
such as prothrombin time (PT), PAI-1, and tPA, which all have equivocal results 
(5,11,18,19). 
Very few studies have analyzed associations between individual PM constituents 
and changes in biomarkers of hemostasis. However, particle mass influences the 
hemostatic response, with no statistically significant changes from pre exposure for 
prothrombin, fibrinogen, FVII, FVIX, vWF, PAI-1, plasminogen, tPA, or fibrin d-dimer 
at 1 hour or at 20 hours after exposure to coarse air particles and a statistically significant 
increase in all of those variables after exposure to fine air particles (56). These fine 
particles are transmitted in concentrated doses while smoking cigarettes. However, the 
main ingredients in Juuls, propylene glycol and glycerine, have not been examined in 
humans for their hematologic effects. 
Purpose 
The purpose of this study is to identify potential differences in hemostatic variables both 
before and after exercise in e-cigarette users versus non-users. 
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Hypothesis 
Resting differences of hemostasis will persist in e-cigarette users immediately following 
acute, maximal exercise. 
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Chapter II 
Methodology 
Subjects 
Forty individuals will be recruited to participate in this research study (20 e-
cigarette users and 20 non-smokers). Subjects will be college-aged (18-35 years of age), 
healthy, and never diagnosed with pulmonary, metabolic, cardiovascular or renal disease. 
The subjects will be matched for physical activity (pa) level between experimental (e-
cigarette users) and the control group (non-smokers) using the long version of the 
International Physical Activity Questionnaire (IPAQ). E-cigarette users will be defined as 
actively smoking e-cigarettes at least 4 days a week. Non-smokers will be defined as not 
having smoked any form of tobacco or marijuana over the past 6 months. Participants 
will be recruited through on campus flyers, a bulk e-mail request to all James Madison 
University faculty and students, and from surrounding areas in the Harrisonburg 
community. Subjects will be excluded if they have any signs or symptoms of 
cardiovascular or metabolic disease, or are asymptomatic but have previously been 
diagnosed with disease. Subjects will also be excluded if they are on any medication that 
could alter their hemostatic variables. Transdermal nicotine or chewing tobacco use will 
be permitted, but the Tobacco Use Questionnaire will be used to screen for and exclude 
combustible tobacco and marijuana usage and baseline testing will be performed to 
confirm subjects’ exhaled carbon monoxide (eCO) < 4 parts per million (ppm).  All 
methods received IRB approval and informed consent will be obtained from all subjects 
prior to testing.  
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Study Design 
All testing will be done before 10:00 am, to control for diurnal influences on the 
variables under examination (2). Subjects will abstain from caffeine and alcohol for 24 
hours before each visit, and have no food or drink other than water for 12 hours before 
their visit. In addition, subjects will be required to refrain from smoking for 3 hours and 
exercise for 24 h before their laboratory visit. Lastly, subjects will be excluded from 
participation if they have any flu or fever symptoms within one week of their lab 
sessions.  
Blood Sampling Assays      
Subjects will assume a semi-recumbent position prior to and following exercise 
testing, 10 mL of blood will be drawn into a citrate anticoagulant solution from an 
antecubital vein using clean venipuncture with minimal stasis. Blood samples will be 
immediately centrifuged for 20 min at 1500g and 4-C to obtain platelet-poor plasma. 
Plasma aliquots will be frozen and stored at -80 degrees C until assayed. Commercially 
available ELISA kits will be used to determine plasma concentrations of coagulation 
FVIII antigen (VisuLize; Ontario, Canada), fibrinogen (Eagle Bioscience, Inc; Nashua, 
NH), active tPA (Eagle Bioscience, Inc; Nashua, NH), tPA antigen (Eagle Bioscience, 
Inc), and active PAI-1(Eagle Bioscience, Inc).  
Incremental Exercise Test 
An incremental test to exhaustion (12-15 minutes) will be performed on an 
electronically braked cycle ergometer (Lode Corival cpet; Groningen, Netherlands) to 
determine the peak rate of oxygen consumption (VO2peak). Resting metabolic measurements 
will be taken for 3 minutes prior to starting the test. Participants will then begin to warm-
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up for approximately 2 minutes at a work rate of 60 watts, always keeping the cadence 
above 50 revolutions per minute (rpm). Work rate will increase by 10 watts per minute 
for females and 20 watts per minute for males. Ventilatory and metabolic data will be 
recorded via a Vmax metabolic measuring system (Carefusion; San Diego, CA). Heart 
rate will be recorded during the test with a PolarLink heart rate monitor and chest strap. 
The test will be terminated when the subject reaches volitional exhaustion or when they 
can no longer maintain 50 rpm. Blood samples will be obtained again within two minutes 
of exercise cessation (15). 
Accelerometer 
Individuals will be asked to wear an Actigraph GT3X accelerometer for seven 
days to objectively measure their moderate-to-vigorous physical activity (MVPA). The 
participants will wear the accelerometers at all times, except while sleeping and 
showering. Freedson cut points will be used to quantify the amount of physical activity 
participants obtain per week (21). Participants will also be asked to keep a log of non-
wear time and report when they put the accelerometer on in the morning and when they 
take the accelerometer off at night. Subjects must wear the accelerometer for a minimum 
of 13 hours a day for the data to count (24). 
Statistical Analysis 
FVIII antigen, fibrinogen, active tPA, tPA antigen, and active PAI-1 will be 
analyzed using repeated measures analysis of variance with exercise as the within-
subjects factor and smoking status as the between-subjects factor. Post hoc comparisons 
will be made using Fisher’s LSD test. A priori statistical significance will be set at P < 
0.05. 
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Abstract 
Background: There is a strong association between factor VIII (FVIII) and presence of 
cardiovascular disease (CVD). Exercise is a known trigger for myocardial infarction, and 
the majority of ischemic events from physical stress occur due to an occlusive thrombus. 
FVIII increases acutely with exercise and remains elevated hours after exercise. 
Furthermore, FVIII is also higher in cigarette smokers, however, it has not been 
investigated in e-cigarette smokers. The purpose of this study is to identify potential 
differences in FVIII before exercise, after exercise, and its magnitude of change in e-
cigarette users versus non-users. 
Methods: Eighteen individuals (8 e-cigarette users, 3 women and 5 men, and 10 non-
smokers, 7 women and 3 men; age, 18-32 years old) were recruited to participate in this 
research study. An incremental test to exhaustion (x̄=12.20 ± 3.20 minutes) was 
performed on an electronically braked cycle ergometer (Lode Corival cpet; Groningen, 
Netherlands) to determine the peak rate of oxygen consumption (VO2peak). Ten mL of 
blood was drawn into a citrate anticoagulant solution from an antecubital vein using clean 
venipuncture with minimal stasis both prior to and immediately following exercise 
testing. A commercially available ELISA kit was used to determine plasma 
concentrations of coagulation FVIII antigen. 
Results: There was no significant difference between smokers (N = 8, 4.35 ± 2.09 IU/ml) 
and nonsmokers (N = 9, 5.02 ± 4.87 IU/ml, p=0.72) for resting FVIII antigen. There was 
a main effect for exercise in that the post-exercise values (N=10, 7.76 ±1.40 IU/ml) were 
larger than pre-exercise values (N=10, 3.82 ± 0.65, p=0.003). However, there was no 
main effect for smoking and no smoking x exercise interaction (post-exercise smokers, 
N=4, 6.67 ± 1.46, post-exercise non-smokers, N= 7, 8.39 ± 5.81, p=0.58). 
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Conclusion: Our preliminary data suggests that e-cig use does not significantly affect 
FVIII or the FVIII response to exercise. 
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Introduction 
 Cardiovascular disease (CVD) is the leading cause of death in the United States, 
manifesting itself through ischemic events such as myocardial infarction and stroke (9). 
There is a strong association between coagulation and presence of CVD. In particular, 
fibrinogen and factor VIII (FVIII), promote coagulation and are linked with risk for CVD 
(12,24), coronary artery disease (CAD) (26,29), myocardial infarction (1,16,29), stroke 
(1,8), and mortality (1,8) in patients with CVD.  
Exercise is a known trigger for myocardial infarction (30), and the majority of 
ischemic events from physical stress occur due to an occlusive thrombus (13). FVIII 
increases acutely with exercise and remains elevated hours after exercise (3,31). FVIII is 
also elevated in cigarette smokers (17), with CVD risk increasing as fibrinogen levels 
increase (18). This may be due to increased inflammation from inhaling particulate 
matter (PM) as inhalation of wood smoke results in acute increases in FVIII (5) and the 
inflammatory cytokine IL-6 has been linked to FVIII (33). In contrast, oral and 
transdermal nicotine use does not chronically influence hemostatic markers in healthy 
adults (7). This suggests the main cause for chronic hematological changes from smoking 
are caused by other PM embedded in the cigarette, such as black carbon, nitrogen 
dioxide, and carbon monoxide which are all transmitted in concentrated doses in 
cigarettes. The evidence also suggests increased fibrinogen levels from PM and ambient 
particles in concentrated doses (6,15,28).  
Recently, e-cigarette smoking has surged in young adults; increasing by 78% 
among high school students from 2017 to 2018 (11). However, the main ingredients in 
Juuls®, propylene glycol and glycerine, have not been examined in humans for their 
hematologic effects. Furthermore, the hematologic response before and after exercise in 
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e-cigarette smokers has not been clearly identified. The purpose of this study is to 
identify potential differences in FVIII both before and after exercise in e-cigarette users 
versus non-users. 
Methodology 
Subjects 
Eighteen individuals were recruited to participate in this research study (8 e-
cigarette users and 10 non-smokers, see Table 1 for demographic characteristics). 
Subjects were free from known pulmonary, metabolic, cardiovascular or renal disease. E-
cigarette users were defined as actively smoking e-cigarettes at least 4 days a week. Non-
smokers were defined as not having smoked any form of tobacco or marijuana over the 
past 6 months. Participants were recruited through on campus flyers, a bulk e-mail 
request to all James Madison University faculty and students, and from the surrounding 
Harrisonburg community. Subjects were also excluded if they were on any medication 
that could alter hemostatic variables (such as aspirin or anti-coagulants). Transdermal 
nicotine or chewing tobacco use was permitted in the smoking group, but the Tobacco 
Use Questionnaire was used to screen for and exclude combustible tobacco and 
marijuana usage and baseline testing was performed to confirm subjects’ exhaled carbon 
monoxide (eCO) < 4 parts per million (ppm).  All methods received IRB approval and 
informed consent was obtained from all subjects prior to testing.          
Study Design 
All testing was done before 10:00 am, to control for diurnal influences on 
hemostasis (2). Subjects abstained from caffeine and alcohol for 24 hours before each 
visit and had no food or drink other than water for 12 hours before their visit. In addition, 
subjects were required to refrain from smoking for 3 hours and exercise for 24 hours 
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before their laboratory visit. Lastly, subjects were excluded from participation if they had 
any flu or fever symptoms within one week of their lab sessions.  
Blood Sampling Assays                                                        
Subjects assumed a semi-recumbent position prior to and following exercise 
testing. Ten mL of blood was drawn into a citrate anticoagulant solution from an 
antecubital vein using clean venipuncture with minimal stasis. Blood samples were 
immediately centrifuged for 20 min at 1500g and 4-C to obtain platelet-poor plasma. 
Plasma aliquots were frozen and stored at -80 degrees C until assayed. A commercially 
available ELISA kit was used to determine plasma concentrations of coagulation FVIII 
antigen (VisuLize; Ontario, Canada). For the FVIII antigen assay, several samples were 
higher than the highest standard used in the ELISA plate. Despite the manufacturer’s 
recommendations, we calculated FVIII for these samples from the standard curve that 
was generated. We successfully obtained pre-exercise blood samples for 8 smokers and 9 
nonsmokers and post exercise blood samples for 4 smokers and 7 nonsmokers. 
Incremental Exercise Test 
An incremental test to exhaustion (12-15 minutes) was performed on an 
electronically braked cycle ergometer (Lode Corival cpet; Groningen, Netherlands) to 
determine the peak rate of oxygen consumption (VO2peak). Resting metabolic 
measurements were taken for three minutes prior to starting the test. Participants then 
began to warm-up for approximately two minutes at a work rate of 60 watts, always 
keeping the cadence above 50 revolutions per minute (rpm). Work rate was increased by 
10 watts per minute for females and 20 watts per minute for males. Ventilatory and 
metabolic data was recorded via a Vmax metabolic measuring system (Carefusion; San 
Diego, CA). Heart rate was recorded during the test with a PolarLink heart rate monitor 
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and chest strap. The test was terminated when subjects reached volitional exhaustion or 
when they could no longer maintain 50 rpm. Blood samples were obtained again within 
two minutes of exercise cessation (10). 
Statistical Analysis 
We performed an independent t-test to compare resting FVIII antigen for the two 
groups.  For the exercise response, we performed a repeated measures analysis of 
variance with exercise (pre, post) as the within-subjects factor and smoking status 
(smoker, non-smoker) as the between-subjects factor.  A priori statistical significance 
was set at P < 0.05. 
Results 
For the baseline comparison of FVIII antigen, there was no significant difference 
between smokers (N = 8, 4.35 ± 2.09 IU/ml) and nonsmokers (N = 9, 5.02 ± 4.87 IU/ml, 
p=0.72). There was a main effect for exercise in that the post-exercise values (N=10, 7.76 
±1.40 IU/ml) were larger than pre-exercise values (N=10, 3.82 ± 0.65, p=0.003). 
However, there was no main effect for smoking and no smoking x exercise interaction 
(Figure 1). Average smoking habits are reported in Table 2. 
Discussion 
 These data suggest that e-cigarette smoking does not affect resting or post-
exercise FVIII antigen. Although there is no comparable resting data on the coagulation 
response in e-cigarettes smokers, our data does contrast what has been found in cigarette 
smokers at rest, who exhibit higher levels of FVIII (144.63 IU/dL) and significantly 
higher levels of plasma fibrinogen (249.4 ± 1.93 mg/dL) compared to non-smokers 
(141.72 IU/dL, p=0.173, 244.4 ± 1.12 mg/dL, p<0.05) (17,32,19). These findings may be 
influenced by smoking volume, however, as hypercoagulability, measured by platelet 
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aggregation, is significantly higher in healthy adults who have smoked greater than 15 
pack years, compared to those who have smoked 5-15 pack years (27). Furthermore, 
those who smoke 20+ cigarettes a day, as compared to those who smoke 1-19 cigarettes a 
day, have significantly higher fibrinogen levels (32). Our e-cigarette smokers had only 
been smoking 21.49 ± 15 months for an average of 22.38 ± 10.95 days a month (Table 2). 
Thus, the volume and/or duration of smoking may have not been sufficient to 
substantially impact FVIII. 
 There is no conclusive evidence in the literature that smoking of any kind has an 
impact on blood coagulation following exercise. In a male monozygotic twins study with 
one twin smoking cigarettes for 20 pack years and the other a nonsmoker, fibrinogen 
tended to be increased among cigarette smokers following exercise but FVIII was not 
significantly different between the two groups (20). This FVIII finding is consistent with 
our results, but does not lead to a clear conclusion on the impact e-cigarettes or smoking 
in general has on blood coagulation, due to our small sample size. We did, however, 
observe a main exercise effect on blood coagulation, as FVIII was elevated following 
exercise in both groups. This is consistent with the literature, as FVIII activity and FVIII 
antigen increase to a similar degree from acute exercise (3,31). 
 The known health risks of traditional cigarettes have been well documented, while 
the risks of e-cigarettes still remain to be less understood. This has potentially contributed 
to increased e-cigarette usage over the past decade. Although e-cigarettes have been 
marketed as being a safer alternative to conventional cigarettes, e-cigarettes still release 
nicotine and concentrated substances that increase the risk of a cardiovascular event (21). 
Our study provides initial findings for a lack of hemostatic changes with e-cigarette 
usage. Further evaluation of the impacts e-cigarettes have on hemostasis and other 
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markers of cardiovascular health still need to be performed, however, as our study only 
measured FVIII antigen. Other hemostatic markers, like fibrinogen, have been seen to be 
positively associated with smoking status (4). Furthermore, when examining the effects 
of e-vapor on hemostasis, there is an e-vapor induced increase in platelet activation that 
was independent of nicotine (14). This suggests that fine particulate matter from e-
cigarettes can lead to increased coagulability. E-cigarettes also lead to the largest levels 
of high sensitive c-reactive protein when compared to both nonsmokers and cigarette 
smokers (22), indicating an increased level of oxidative stress and inflammation similarly 
found in smokers (33) which can further increase risk for CVD. The correlation between 
this increase in inflammation found in e-cigarette users and any changes in hemostatic 
markers has yet to be examined. However, the nicotine (23), aerosol (25), and particulate 
matter (25) in e-cigarettes have all been found to influence individual risks of CVD. 
 Our study did have some major limitations that could have impacted our findings. 
Definitive conclusions cannot be made because of our low sample size and the 
inappropriate analysis of FVIII in samples that exceed the highest standard ELISA kit. 
This makes our findings preliminary, however, they can potentially be used for sample 
size calculations for future studies evaluating the effect size of e-cigarette use on 
hemostasis. Further limitations include the non-standardization of both smoking duration 
and smoking vessel, making it difficult to draw specific conclusions from our 
participants. However, the diversity in our e-cigarette smoking pool is more 
representative of the smoking population as a whole who typically smoke various brands 
and have varying durations of active smoking. Finally, we did not investigate the 
different in e-cigarette compositions that can potentially alter hemostasis. To better 
understand the potential mechanisms e-cigarettes have on CVD risk and to further 
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identify differences between e-cigarettes and conventional cigarettes, future studies 
should isolate the compounds and report their effects. 
 In conclusion, our preliminary data suggests that e-cig use does not significantly 
affect FVIII or the FVIII response to exercise. 
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Figure 1. Pre and Post-Exercise Values of Factor VIII (FVIII) Antigen in Smokers and 
Nonsmokers 
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Figure Legend 
Table 1. Subject Demographics between Women and Men in Smokers and Non-smokers  
*-Significantly different than non-smoking women, p=0.003 
Table 2. Average Smoking Habits of E-Cigarette Smokers 
Figure 1. Pre and Post-Exercise Values of Factor VIII (FVIII) Antigen in Smokers and 
Nonsmokers 
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Chapter IV 
Appendices 
Appendix A 
Informed Consent 
Project Title: The impact of varying physical activity levels on airway inflammation, 
airway hyperresponsiveness and hemostasis in e-cigarette smokers 
 
Consent to Participate in Research  
 
Identification of Investigators and Purpose of Study  
You are being asked to participate in a research study conducted by Drs. 
Stephanie Kurti and Christopher Womack from James Madison University. To 
participate, you must be an electronic cigarette user or nonsmoker with no previous 
history of cardiovascular, renal, and metabolic disease. The purpose of this study is to 
determine if varying physical activity levels in e-cigarette users impacts airway 
inflammation, airway hyperresponsiveness, and hemostasis. Previous research has shown 
that e-cigarette use results in lower lung function compared to nonsmokers, but the 
degree of lung function is much lesser compared to exclusive conventional tobacco 
cigarette users. Moreover, exclusive conventional tobacco cigarette use increases blood 
coagulation and decreases fibrinolysis compared to nonsmokers, but no investigation has 
looked at e-cigarette use. Therefore our aim is to determine whether e-cigarette use is 
causing damage to the airways before pulmonary function decline is observed as well the 
impact it has on hemostatic variables at varying physical activity levels. This study will 
contribute to the knowledge of both practitioners and clinicians, and may provide an 
important public health message in providing recommendations for physical activity 
levels that would have a protective effect in those who smoke e-cigarettes and/or 
conventional tobacco cigarettes chronically.  Should you decide to participate in this 
research study, you will be asked to sign this consent form once all your questions have 
been answered to your satisfaction.  
 
Research Procedures  
This study consists of questionnaires, a body composition scan, tracking physical 
activity, one VO2peak tests, pulmonary function tests, exhaled gas measurements, and 
hypertonic saline challenges which will be administered to individual participants in the 
Human Performance Laboratory at James Madison University.  
The specific procedures during each visit are included here: 
Initial visit: On the first visit to the laboratory, a researcher will go over informed 
consent with you as well as begin the process of completing all questionnaires including 
the international physical activity questionnaire, and the Physical Activity Readiness 
questionnaire-Plus, and tobacco use questionnaire.  
After completion of the questionnaires, we will obtain your height, weight, waist 
circumference, and DEXA scan measurements to assess your body composition.You will 
then perform an incremental exercise test to exhaustion on a cycle ergometer. 
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Ventilatory, metabolic and heart rate data will be recorded for the entirety of the test until 
you reach volitional fatigue at which the test will be terminated. Before and after the 
exercise testing session, you will perform standard pulmonary function tests 2 minutes 
and 10 minutes after the bout of exercise. Upon completion of the exercise session, you 
will be given an accelerometer to wear for one week, which will you return on your 
second visit. 
Incremental exercise test to exhaustion: You will ride on an electronically 
braked cycle ergometer approximately 12-15 minutes to determine VO2peak. Your resting 
metabolic measurements will be taken for 3 minutes prior to starting the test. You will 
begin the test with a 2 minute warm-up, pedalling at 50 revolutions per minute at work 
rate of 50 watts. Work rate will increase each minute by 10 watts for females and 20 
watts for males. Your ventilatory and metabolic data will be recorded through breath by 
breath analysis. Your heart rate will be recorded during and throughout the test with a 
heart rate monitor and chest strap. A pulse oximeter will be secured to your left earlobe to 
estimate arterial oxygen saturation. After each stage of the test, you will be asked to 
report your RPE (rating of perceived exertion) as well as how difficult breathing feels to 
you(sensation of dyspnea). The VO2peak test will be terminated when you can no longer 
continue exercise or maintain 50 revolutions/minute pedal frequency and have reached 
volitional fatigue. You may end the test whenever you want if you feel uncomfortable. 
Initial blood samples will be repeated at the end of the exercise test, within two minutes 
of ending the exercise.  
Pulmonary function tests: You will perform a maximum flow-volume loop 
where you  maximally inhale, forcefully exhale for 6 seconds and then maximally inhale 
into a spirometer while wearing a nose-clip. This will record forced expiratory volume in 
one-second, forced vital capacity, forced expiratory flow between 25 and 75% of forced 
vital capacity , and peak expiratory flow. Then using impulse oscillometry, you will 
breathe normally on a mouthpiece while the machine records resistance in your airway. 
Finally you will be asked to take a brief, maximal inhale at the end of a normal breath for 
every stage of the test. This is an experimental test to determine whether the you are 
experiencing expiratory flow limitation during exercise. It is a simple breathing maneuver 
that poses no risk to you.  
Accelerometry: You will be asked to wear an accelerometer for 7 days around 
your waist to track your physical activity. A researcher will guide you on how to 
appropriately place the accelerometer on. 
Second and third visit: You will come into the laboratory in the morning after an 
overnight fast at which your blood pressure will be taken and 10 mL of your blood will 
be collected via a serial venipuncture in the antecubital vein. Then you will exhale into a 
nitric oxide analyzer for 6 seconds two times to measure your exhaled nitric oxide as a 
measure of airway inflammation. You will then perform standard pulmonary function 
testing via the maximum flow volume loop. Following this, you will perform both the 
hypertonic saline challenge and hypertonic saline challenge with deep inspirations each 
on different days for 20 minutes, and then perform pulmonary function testing 
immediately after.  
 Hypertonic saline challenge session: You will breathe in 25% hypertonic saline 
(salt and water) from an over-the-counter ultrasonic nebulizer that converts the salt 
solution from a liquid to a mist. You will breathe normally on the nebulizer for 20 
minutes while seated comfortably and wearing a nose clip.  
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 Hypertonic saline challenge with deep inspiration session: You will complete 
the exact same protocol as the hypertonic saline challenge session plus perform 5 deep 
inspirations immediately after the hypertonic saline challenge and prior to the pulmonary 
function tests.  
 
Risks 
Participation in this study does have some small risks. The risk of any serious event 
during this study is minimal.  Possible risks include: 
 Hypertonic saline challenge: You may experience irritation, coughing, 
wheezing, and/or bronchoconstriction (may be like asthma-like symptom in severe cases) 
after inhaling this saline solution. 
 Venipuncture: You may experience mild bruising, risk of transfer of blood borne 
pathogens, infection, and/or skin irritation when blood is taken intravenously.  
 DEXA: The DEXA scan entails a low dose of radiation equivalent to 
approximately one transatlantic flight (0.015 mSv= milliseievert). While there is no 
validated questionnaire to define extensive exposure, radiation exposure is cumulative 
over the lifespan (200 DEXA scans is equal to the cumulative exposure of living at sea 
level for a year (3 mSv). DEXA scans carry minimal X-ray exposure.  To minimize 
exposure, the DEXA scan will only be performed once. All body composition assessment 
will be performed according to the American College of Sports Medicine guidelines for 
body composition assessment. 
 
Benefits 
By participating in this study, you will learn about your current pulmonary health and 
function (airway inflammation, airway hyperresponsive, forced expiratory flow in one-
second, forced vital capacity, forced expiratory flow at 25-75% of vital capacity), 
VO2peak, and body composition. Your data will be provided to you upon completion of 
your participation in the study. If an emergency arises and you must dropout, you may 
still receive your data.  
 
Society will benefit from more knowledge about how e-cigarette usage may influence 
adverse vascular and pulmonary outcomes, as well as how lifestyle may influence these 
outcomes.  
 
Confidentiality  
The results of this project will be coded in such a way that the respondent’s identity will 
not be attached to the final form of this study.  The researcher retains the right to use and 
publish non-identifiable data.  While individual responses are confidential, aggregate data 
will be presented representing averages or generalizations about the responses as a 
whole.  All data will be stored in a secure location accessible only to the JMU 
researchers.  Upon completion of the study, all information that matches up individual 
respondents with their answers will be destroyed.  
 
Participation & Withdrawal  
Your participation is entirely voluntary.  You are free to choose not to participate.  
Should you choose to participate, you can withdraw at any time without consequences of 
any kind. 
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Questions about the study  
If you have questions or concerns during the time of your participation in this study, or 
after its completion or you would like to receive a copy of the final aggregate results of 
this study, please contact: 
Researcher’s Name: Dr. Stephanie Kurti                Department of Kinesiology               
Email Address: kurtisp@jmu.edu                             James Madison University 
Cell-Phone number: 630-205-6363  
Telephone:  540-568-3947 
 
Researcher’s Name: Dr. Christopher Womack  Department of Kinesiology  
Email Address: womackcx@jmu.edu  James Madison University  
 
Telephone: 540-658-6145 
Questions about Your Rights as a Research Subject 
Dr. David Cockley 
Chair, Institutional Review Board 
James Madison University 
(540) 568-2834 
cocklede@jmu.edu  
Giving of Consent 
I have read this consent form and I understand what is being requested of me as a 
participant in this study.  I freely consent to participate.  I have been given satisfactory 
answers to my questions.  The investigator provided me with a copy of this form.  I 
certify that I am at least 18 years of age. 
______________________________________  
Name of Participant (Printed) 
  
______________________________________ ______________ 
Name of Participant (Signed)                                 Date 
______________________________________ ______________ 
Name of Researcher (Signed)                                Date 
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Appendix B 
The Physical Activity Readiness Questionnaire 
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Appendix C 
Tobacco Use Questionnaire 
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